Coronaviruses: A patent dataset report for research and development (R&D) analysis

Searching and analyzing patent-relevant Covid-19 information

The COVID-19 pandemic has prompted several institutions to offer free, dedicated websites and tools to foster research and access to urgently needed innovative solutions by facilitating the search and analysis of information within the large amount of scientific and patent literature which was published since January 2020. This situation is clearly exceptional and challenging for patent information users searching for relevant disclosures at a given date in a reliable manner. This article provides an overview of search criteria and strategies, main databases and websites, number of publications, biological sequence information and experimental data sets covering COVID-19 findings within scientific and patent literature have been disclosed between January and August 2020. The analysis of non-patent literature has been focused on the identification, date assignment, disambiguation, and access to experimental data. The analysis of patent literature has been focused on the trends found within the earliest filed and published patent documents in representative jurisdictions worldwide. Some practical advice and strategies for technical, medical, or patentability assessment of COVID-19-related innovations across different information formats and resources are proposed.

Global landscape of patents related to human coronaviruses

At present, the COVID-19 pandemic is running rampant, having caused 2.18 million deaths. Characterizing the global patent landscape of coronaviruses is essential not only for informing research and policy, given the current pandemic crisis, but also for anticipating important future developments. While patents are a promising indicator of technological knowledge production widely used in innovation research, they are often an underused resource in biological sciences. In this study, we present a patent landscape for the seven coronaviruses known to infect humans. The information included in this paper provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines along with a deeper discussion of intellectual property rights under epidemic conditions. The results show that there has been a rapid increase in human coronavirus patents, especially COVID-19 patents. China and the United States play an outstanding role in global cooperation and patent application. The leading role of academic institutions and government is increasingly apparent. Notable technological issues related to human coronaviruses include pharmacochemical treatment, diagnosis of viral infection, viral-vector vaccines, and traditional Chinese medicine. Furthermore, a critical challenge lies in balancing commercial competition, enterprise profit, knowledge sharing, and public interest.

Coronavírus: exame preliminar da trajetória científica e tecnológica dos surtos

Traça um exame preliminar de como se constituiu a relação entre manifestações da doença, descobertas científicas e produção tecnológica para os principais surtos de coronavírus, entre 2000 a 2020, de modo a adensar conhecimentos que possam corroborar para a compreensão ampliada da pandemia. Adota como assuntos basilares para a revisão bibliográfica a interlocução entre ciência, tecnologia e inovação bem como os aspectos relevantes para compreensão da trajetória da família coronavírus: principais surtos (2002, 2012 e 2019) e descobertas científicas. Apresenta uma linha do tempo dos surtos provocados pelo vírus visando compor um quadro com a trajetória das principais descobertas realizadas pela comunidade científica que estuda a temática, apoiada nos estudos de Weiss (2020). Por meio de um estudo de anterioridade realizado no Questel Orbit, dimensiona os pedidos de patentes por família existentes destacando o período temporal da publicação, principais países de depósito, clusters e domínios tecnológicos e série histórica pela Classificação Internacional de Patentes (CIP). Avalia as trajetórias expostas e conclui que é necessário um maior alinhamento entre a ciência, a tecnologia e a inovação para promover respostas rápidas e contundentes para as doenças geradas pelo Coronavírus